{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T15:22:59Z","timestamp":1725031379970},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1053\/j.ackd.2006.10.004","type":"journal-article","created":{"date-parts":[[2007,5,9]],"date-time":"2007-05-09T14:42:19Z","timestamp":1178721739000},"page":"44-53","source":"Crossref","is-referenced-by-count":12,"title":["Management of Chronic Kidney Disease Mineral-Bone Disorder"],"prefix":"10.1053","volume":"14","author":[{"given":"Stephen Z.","family":"Fadem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon M.","family":"Moe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2006.10.004_bib1","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1523-1755.2005.00184.x","article-title":"Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients","volume":"67","author":"Nakanishi","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib2","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2004.12.011","article-title":"Secondary hyperparathyroidism: Review of the disease and its treatment","volume":"26","author":"de Francisco","year":"2004","journal-title":"Clin Ther"},{"key":"10.1053\/j.ackd.2006.10.004_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jsbmb.2004.03.061","article-title":"1,25-Dihydroxyvitamin D downregulation of TGFalpha\/EGFR expression and growth signaling: A mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure","volume":"89-90","author":"Dusso","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1053\/j.ackd.2006.10.004_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.RES.0000141775.67189.98","article-title":"Pathophysiology of vascular calcification in chronic kidney disease","volume":"95","author":"Moe","year":"2004","journal-title":"Circ Res"},{"key":"10.1053\/j.ackd.2006.10.004_bib5","doi-asserted-by":"crossref","DOI":"10.1210\/er.2005-0019","article-title":"The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: Frp-4, MEPE, and FGF23","author":"White","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1053\/j.ackd.2006.10.004_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1525-139X.2003.16037.x","article-title":"Hidden sources of phosphorus in the typical American diet: Does it matter in nephrology?","volume":"16","author":"Uribarri","year":"2003","journal-title":"Semin Dial"},{"key":"10.1053\/j.ackd.2006.10.004_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/jn\/107.1.42","article-title":"Physiological responses of human adults to foods containing phosphate additives","volume":"107","author":"Bell","year":"1977","journal-title":"J Nutr"},{"key":"10.1053\/j.ackd.2006.10.004_bib8","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/ndt\/17.8.1419","article-title":"Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency","volume":"17","author":"Hsu","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.10.004_bib9","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.ajkd.2005.02.029","article-title":"Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States","volume":"45","author":"LaClair","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib10","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1053\/ajkd.2001.20740","article-title":"Role of phosphorus in the pathogenesis of secondary hyperparathyroidism","volume":"37","author":"Slatopolsky","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"suppl","key":"10.1053\/j.ackd.2006.10.004_bib11","first-page":"S1","article-title":"Clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"K\/DOQI","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000421918","article-title":"Aluminum and renal disease","volume":"102","author":"Alfrey","year":"1993","journal-title":"Contrib Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1056\/NEJM197601222940402","article-title":"The dialysis encephalopathy syndrome","volume":"294","author":"Alfrey","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2006.10.004_bib14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1172\/JCI113886","article-title":"Reduction of dietary phosphorus absorption by phosphorus binders","volume":"83","author":"Sheikh","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ackd.2006.10.004_bib15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0272-6386(12)80496-3","article-title":"Calcium acetate control of serum phosphorus in hemodialysis patients","volume":"17","author":"Emmett","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.ajkd.2003.10.014","article-title":"Cardiac calcification in renal patients: What we do and don\u2019t know","volume":"43","author":"Hujairi","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib17","first-page":"205","article-title":"Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: A systematic review","volume":"17","author":"McCullough","year":"2004","journal-title":"J Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib18","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","article-title":"A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"33","author":"Bleyer","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1523-1755.1999.00240.x","article-title":"RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone","volume":"55","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib21","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/ndt\/gfh894","article-title":"Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density","volume":"20","author":"Asmus","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.10.004_bib22","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib23","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1523-1755.2004.00590.x","article-title":"Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)","volume":"65","author":"Qunibi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0272-6386(03)00554-7","article-title":"Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia","volume":"42","author":"Joy","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib25","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/ndt\/gfh282","article-title":"Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: A 4-week, dose-finding, open-label study with lanthanum carbonate","volume":"19","author":"Hutchison","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.10.004_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5414\/CNP65191","article-title":"Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: Safety and efficacy in chronic maintenance hemodialysis patients","volume":"65","author":"Finn","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5414\/CNP63127","article-title":"Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats","volume":"63","author":"Damment","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib28","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up","volume":"21","author":"Spasovski","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.10.004_bib29","first-page":"428","article-title":"The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease","volume":"64","author":"Freemont","year":"2005","journal-title":"Clin Nephrol"},{"issue":"suppl","key":"10.1053\/j.ackd.2006.10.004_bib30","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","article-title":"A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients","volume":"85","author":"D\u2019Haese","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib31","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ki.1994.342","article-title":"Evidence for abnormal calcium homeostasis in patients with adynamic bone disease","volume":"46","author":"Kurz","year":"1994","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib32","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","article-title":"Arterial calcifications and bone histomorphometry in end-stage renal disease","volume":"15","author":"London","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2215\/CJN.00560206","article-title":"The case against calcium-based phosphate binders","volume":"1","author":"Moe","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib34","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/ndt\/17.9.1643","article-title":"A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients","volume":"17","author":"McIntyre","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.10.004_bib35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.V95859","article-title":"Nocturnal hemodialysis: Three-year experience","volume":"9","author":"Pierratos","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2003.12.003","article-title":"Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy","volume":"43","author":"Martin","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.ki.5001606","article-title":"Inter-method variability in PTH measurement: Implication for the care of CKD patients","volume":"70","author":"Souberbielle","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib38","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00198-005-1867-7","article-title":"Estimates of optimal vitamin D status","volume":"16","author":"Dawson-Hughes","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000081023","article-title":"Vitamin D insufficiency and deficiency in chronic kidney disease","volume":"24","author":"Gonzalez","year":"2004","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib40","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","article-title":"Vitamin D3 and calcium to prevent hip fractures in the elderly women","volume":"327","author":"Chapuy","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2006.10.004_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1525-139X.2005.18402.x","article-title":"Vitamin D for health and in chronic kidney disease","volume":"18","author":"Holick","year":"2005","journal-title":"Semin Dial"},{"key":"10.1053\/j.ackd.2006.10.004_bib42","unstructured":"Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D and blood pressure in the Third Tational Health and Nutritional Examination Survey. Proceedings of the 13th Workshop on Vitamin D: 512006"},{"issue":"suppl 10","key":"10.1053\/j.ackd.2006.10.004_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ndt\/17.suppl_10.10","article-title":"Vitamin D analogues for secondary hyperparathyroidism","volume":"17","author":"Brown","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.10.004_bib44","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 3","key":"10.1053\/j.ackd.2006.10.004_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ndt\/13.suppl_3.68","article-title":"Intermittent oral 1-alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients","volume":"13","author":"Frazao","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.10.004_bib46","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1-alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism","volume":"36","author":"Frazao","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1997.39","article-title":"Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism","volume":"51","author":"Tan","year":"1997","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib48","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/ajkd.1998.v32.pm9708607","article-title":"Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism","volume":"32","author":"Akiba","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib49","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0272-6386(01)80010-X","article-title":"Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1-alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: A sequential comparison","volume":"37","author":"Maung","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"suppl","key":"10.1053\/j.ackd.2006.10.004_bib50","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1053\/ajkd.2003.50097","article-title":"Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients","volume":"41","author":"Yasuda","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib51","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0272-6386(95)90455-7","article-title":"A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia","volume":"26","author":"Slatopolsky","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib52","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","article-title":"Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients","volume":"40","author":"Coyne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib53","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib54","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2006.10.004_bib55","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: A historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib56","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","article-title":"Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study","volume":"70","author":"Melamed","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib58","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.ackd.2006.10.009","article-title":"Vitamin D in patients with kidney disease: Cautiously optomistic","volume":"14","author":"Thadani","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib60","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ki.1995.292","article-title":"The pathogenesis of parathyroid gland hyperplasia in chronic renal failure","volume":"48","author":"Drueke","year":"1995","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib61","doi-asserted-by":"crossref","first-page":"774","DOI":"10.7326\/0003-4819-88-6-774","article-title":"1,25 dihydroxycholecalciferol effects in chronic dialysis: A double-blind controlled study","volume":"88","author":"Berl","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2006.10.004_bib62","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","article-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4","volume":"43","author":"Coburn","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib63","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.10.004_bib64","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/366575a0","article-title":"Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid","volume":"366","author":"Brown","year":"1993","journal-title":"Nature"},{"key":"10.1053\/j.ackd.2006.10.004_bib65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.semnephrol.2003.08.017","article-title":"Calcium-sensing receptors","volume":"24","author":"Goodman","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib66","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1523-1755.2000.00183.x","article-title":"A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism","volume":"58","author":"Goodman","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib67","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib68","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium \u00d7 phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2006.10.004_bib69","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2006.10.004_bib70","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000073945","article-title":"Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product","volume":"23","author":"Moe","year":"2003","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ackd.2006.10.004_bib71","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/ndt\/gfh966","article-title":"Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl","volume":"20","author":"Moe","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.10.004_bib72","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559506001662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559506001662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T07:16:30Z","timestamp":1628838990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559506001662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S1548559506001662"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2006.10.004","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}